Christopher Liu
Stock Analyst at Leerink Partners
(2.49)
# 2,300
Out of 4,893 analysts
5
Total ratings
50%
Success rate
23.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.74 | +381.93% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $22.62 | +19.36% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $80.60 | -47.89% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $45.15 | -60.13% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.74
Upside: +381.93%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $22.62
Upside: +19.36%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $80.60
Upside: -47.89%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $45.15
Upside: -60.13%